April 27, 2018 09:29 AM EDT

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

Amber Tong

Betting on the biotech boom that’s now focusing considerable attention on China, WuXi AppTec has doubled down on its investment in one of its Shanghai …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ahead of Hong Kong list­ing changes, WuXi preps for a biotech boom with a new R&D cen­ter in Shang­hai

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai